Equivu Capital Announces Sale of Atlantic Power Constructors
BOCA RATON, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Equivu Capital ('Equivu'), a South Florida-based private investment firm, today announced the sale of Atlantic Power Constructors ('APC'), a leading provider of electrical replacement, upgrade, and maintenance services, based in Manchester, Maine. William Blair acted as the exclusive financial advisor to Atlantic Power Constructors in connection with the transaction.
During Equivu's investment period beginning in 2023, APC grew revenue by over five times and expanded the business from its original operations in Maine throughout the Northeast and mid-Atlantic.
'We are incredibly proud of the expansion and success of APC,' said Sal Calvino, Founder of Equivu. 'The team at APC is second to none and we really enjoyed scaling this business with all of them.'
About APC
Atlantic Power Constructors, an electrical infrastructure services company, was formed by industry veterans with a combined more than 100 years of power sector experience. The company provides a full range of power grid solutions across transmission, distribution, and substation infrastructure, in addition to 24/7 storm restoration. For more information, please visit www.useapc.com.
About Equivu Capital
Equivu was founded by Sal Calvino in late 2020 with the idea that the team at Equivu would not only invest in growing businesses but bring a high level of management experience to companies in which Equivu commits its capital. Our mission is to be a visionary partner dedicated to building a strong foundation for success through transparent communication and collaborative efforts. We scale businesses by providing strategic and operational support, fostering entrepreneurial spirit, and promoting equity in every aspect of our work. With a focus on mentoring and leadership, we empower individuals and organizations to evaluate opportunities, optimize efficiency, and achieve lasting growth. Together, we create a structure for progress that is rooted in purpose, open communication, customer satisfaction and a shared commitment to excellence. For more information, please visit www.equivu.com.
For more media information, contact:
Lisa Hendrickson, LCH Communications for Equivu
516-643-1642
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
TELO Rises on Promising Telomir-1 Preclinical Results
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is among the 10 Best Growth Stocks Under $100 to Buy Now. On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) revealed that its leading product, Telomir-1, showcased a marked improvement in the neurological, liver, and kidney symptoms observed in a preclinical animal model of Wilson's disease. In a zebrafish model mimicking Wilson's disease, the drug showed substantial dose-dependent improvements, including a decrease in tremors, a normal swimming behavior, and a 50% reduction in copper accumulation in liver tissue. It also led to better liver and kidney histopathology while restoring key biomarkers. As Dr. Angel, Chief Scientific Advisor at Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), mentioned, 'These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson's disease.' A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment. With a market capitalization of $59.079 million, the company is also positioning its drug through IND-enabling studies, with plans to submit its first IND for a rare disease by the year's end, followed by human trials in the first half of the next year. Analysts have set a price target of $15.50 for Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), implying an upside of a whopping 688%. These well-structured plans highlight the company's position to lead the global market in the years ahead. Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage biopharmaceutical company that emphasizes the reversal of oxidative stress, cellular protection, and regulatory mechanisms. Incorporated in 2021, this Florida-based company is designing and developing products to address the causes of rare diseases. While we acknowledge the potential of TELO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
an hour ago
- Associated Press
Sarasota Medical Products, Inc. Celebrates 15 Years of Innovation, Partnership, and Purpose in Medical Adhesives
06/13/2025, Sarasota, Florida // PRODIGY: Feature Story // Sarasota Medical Products, Inc. (SMP), a veteran-owned innovator in the field of medical device adhesives, is proudly celebrating its 15th anniversary. It is a milestone that reflects its unwavering commitment to innovation, trusted partnership, and elevating the standard of care for patients worldwide. Founded in 2010 by Dr. Walter Francis Leise III, SMP began as an ambitious idea on paper, an MBA business plan, and a leap of faith away from corporate life. Today, the company stands as a recognized innovator in custom hydrocolloid development and wound, ostomy, and incontinence care, with a legacy of breakthroughs, partnerships, and purpose-driven growth. The turning point in SMP's early days came unexpectedly on Christmas Eve in 2011. Dr. Leise was in the lab, frustrated by an adhesive formulation that didn't meet expectations. But inspiration struck the next morning. 'I realized the formulation could actually serve a completely different need,' he said. 'It turned out to be perfect as a moldable gasket for ostomy patients. That moment really encapsulated what we now do: adapt, innovate, and listen to what patients need.' That adaptability became the cornerstone of SMP's success. SMP closely works with partners to develop customized, premium adhesive solutions. Each formulation is created with patients in mind. 'We're not a 'take it or leave it' company,' said Dr. Leise. SMP dwells on the philosophy that good products come from great partnerships. It only works with vendors who want to be partners, not just buyers. And the SMP team speaks to the patients constantly to hear them out, especially if something's not working, and constantly works on innovation. This commitment has led them to key acquisitions and brand expansions that reinforce SMP's standing in the market. In 2019, SMP acquired Cymed, a premium brand tailored for active patients. Employing micro skin, a breathable, ultra-thin, water-resistant adhesive dressing, Cymed empowers users to move freely, exercise, swim, and live without limits. 'Cymed is for people who don't want to slow down,' said Dr. Leise. 'It's one of the oldest names in ostomy care, and we're proud to carry it forward with next-gen improvements.' In 2020, SMP acquired Entrust, now housed under its Fortis Medical Products division. Known for high-quality ostomy, ileostomy, and urostomy devices, Entrust was brought under the SMP umbrella during the COVID-19 crisis, preserving a trusted brand and giving it the operational strength to grow. 'With Entrust, the mission is trust,' said Dr. Leise. 'Patients deserve to forget they've had a life-changing surgery. Our job is to make products so dependable and comfortable, their dignity and quality of life are never in question.' Based in Florida, SMP maintains its U.S.-made advantage, allowing it to maintain cost-competitive pricing against Asian manufacturers, all while offering unmatched customization and quality. Innovations in process efficiency have further strengthened SMP's position. The company has developed proprietary methods that dramatically reduce labor requirements and production costs, without compromising product performance. These efficiencies enable SMP to keep prices low, expand globally, and reinvest in research and development, including groundbreaking ventures into antibacterial adhesives. Looking ahead, SMP is launching a new brand, Ndur Healthcare, featuring a skincare line powered by natural ingredients like tallow, alongside anti-aging and acne care innovations. A major highlight is Magic Shields, a patented, FDA-approved, silver-free antibacterial hydrocolloid that kills MRSA and E. coli, reduces fungal infections, and supports wound healing. Magic Shields is designed to serve both skincare and wound care needs, showcasing SMP's expanding footprint in preventive health. Over the past decade and a half, SMP has gone from a single formulation to hundreds of private-label products, serving more than 20 companies. 'I'm proud we're still here,' said Dr. Leise. 'It's easy to underestimate the grit it takes to survive and grow in this industry. But I believe in working hard every day so that when luck comes, we're ready for it.' As Sarasota Medical Products celebrates this 15-year milestone, the company remains anchored in its mission: to empower patients to live confidently, comfortably, and with dignity, one innovative adhesive at a time. Media Contact Name: Rachel Crumbley Email: [email protected] The content provided herein does not constitute medical advice. Any references to treatments, products, or services are not intended as endorsements. The company and its affiliates are not responsible for the accuracy, reliability, effectiveness, or correct use of information contained in this press release.
Wall Street Journal
2 hours ago
- Wall Street Journal
Why Are We Paying So Much for Electricity?
'Summer Electric Bills Set to Climb' (U.S. News, June 9) highlights the rising cost of electricity that will be felt by families and businesses everywhere this summer. This problem isn't caused by a lack of supply to meet growing demand. Rather, this country has failed to build the energy infrastructure necessary to transport America's abundant natural resources efficiently. In other words, the problem could have been avoided with adequate energy infrastructure, particularly in the Northeast. Between 2013 and 2021, at least five major natural-gas pipeline projects were canceled in the region because of state officials' denial of permits and excessive delays, which made the projects unviable.
